Arrowstreet Capital’s OptimizeRx OPRX Stock Holding History

Arrowstreet Capital’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,085	Closed	-$352K	–	1409
2023 Q1	$352K	Buy	+24,085	New	+$403K	﹤0.01%	1224

Other funds holding OPRX

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Arrowstreet Capital's OPRX Position: Q2 2023 in Review

Arrowstreet Capital sold out of OptimizeRx (OPRX) in Q2 2023, closing a stake of 24,085 shares — an estimated $352K sold.

Arrowstreet Capital first reported a position in OPRX in Q1 2023 and held it in 1 quarter. The position peaked at $352K in Q1 2023. 102 funds tracked by Wall St. Rank hold OPRX as of Q2 2023.

Arrowstreet Capital reported no remaining OptimizeRx position as of Q2 2023 after selling out during the quarter.
Arrowstreet Capital sold 24,085 OptimizeRx shares in Q2 2023, an estimated $352K.
Arrowstreet Capital first reported a position in OptimizeRx in Q1 2023 and held it in 1 quarter.
Arrowstreet Capital's OptimizeRx position peaked at $352K in Q1 2023.
102 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2023.

Based on Arrowstreet Capital's 13F filing for Q2 2023, filed 14 Aug 2023.